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The nucleotide sequence of a plasmid-borne trimethoprim resistance gene from a commensal fecal Esche-
richia coli isolate revealed a new dihydrofolate reductase gene, dfrXV, which occurred as a gene cassette inte-
grated in a site-specific manner in a class 1 integron. The new gene shows 84% nucleotide identity and the
predicted protein shows 90% amino acid identity with dfrI and DHFR type I, respectively. Genes for spectino-
mycin resistance, aadA1 [ant (3**)-Ia], and sulfonamide resistance, sulI, were located downstream of dfrXV in
a manner identical to that in pLMO229.
Trimethoprim is an antimicrobial agent used on its own or in
combination with sulfamethoxazole in the treatment of infec-
tions caused by gram-negative organisms. Trimethoprim selec-
tively inhibits the bacterial dihydrofolate reductase (DHFR),
thus preventing the reduction of dihydrofolate to tetrahydro-
folate (8). The most common mechanism of resistance to tri-
methoprim in enterobacteria is the production of an additional
plasmid-mediated DHFR which, unlike the chromosomal en-
zyme, is less sensitive to inhibition by trimethoprim (5). Sixteen
trimethoprim resistance enzymes have been identified in en-
terobacteria and have been characterized and grouped on the
basis of their nucleotide sequences and kinetic properties. The
largest of these groups and by far the most prevalent are the
type I-like enzymes, which include dfrI, dfrIb, dfrV, dfrVI, and
dfrVII (14). This enzyme group is characterized by an open
reading frame (ORF) of 157 amino acid residues, and the
members of this group share between 64 and 88% amino acid
sequence identity in this ORF (14). The majority of these en-
zymes have been found as gene cassettes inserted into the
recombinationally active sites of integrons (22). In a survey of
trimethoprim resistance in South Africa, 357 isolates of gram-
negative, aerobic, commensal fecal flora were probed with oli-
gonucleotide probes to determine the prevalence of DHFR
resistance genes within the population (2, 3). Hybridization ex-
periments revealed that contrary to all previous data, the most
prevalent DHFR was type Ib (21.8%), followed by types VII
(18.8%), I (14.6%), VIII (12.9%), XIII (12.3%), V (7.8%), and
XII (0.3%) (1, 3). Forty-six of 357 isolates did not hybridize
to any of the DHFR probes. One of these isolates, Escherich-
ia coli UI14, which is highly resistant to trimethoprim (MIC,
.2,048 mg/ml), was shown to transfer a 101-kb plasmid
(pUK2317) which confers resistance to trimethoprim, specti-
nomycin, tetracycline, and sulfonamides to a recipient strain,
E. coli J62-2, by conjugation (4).
MATERIALS AND METHODS
Purified pUK2317 DNA was restricted with PstI, and the fragments were
ligated into PstI-restricted pGEM-3Zf(1) (Promega, Madison, Wis.) and elec-
trotransformed (10) into E. coli JM109. A trimethoprim-resistant transformant,
pUK2411, which contained a 9.4-kb PstI fragment was further restricted with
BamHI, and the 6.74-kb fragment which contained the plasmid vector and a
3.54-kb cloned fragment were religated to produce trimethoprim-resistant clone
pUK2412. A 1,280-bp PvuII fragment was further subcloned in both directions
into the SmaI site of pGEM-3Zf(1) to produce trimethoprim-resistant clones
pUK2413 and pUK2414. These two plasmids were then restricted with HindIII
and were religated to produce trimethoprim-sensitive clones pUK2415 and
pUK2416. Cloning was performed as described previously (23), and sequencing
reactions were performed with both dGTP and dITP labels with the SEQUE-
NASE, version 2.0, DNA sequencing kit (United States Biochemicals, Cleveland,
Ohio). Sequence comparisons were made with the BLAST computer program
(National Center for Biotechnology Information).
Nucleotide sequence accession number. The nucleotide sequence of the type
XV DHFR has been given EMBL accession no. Z8331.
RESULTS AND DISCUSSION
Figure 1 shows the restriction map, gene map, and direction
of sequencing of pUK2412. From the partial sequence and re-
striction map, the trimethoprim resistance gene was shown to
be preceded by the intI1 gene associated with a class 1 inte-
gron, as reported previously (12, 16, 19, 24). A primer (59-AA
CGATGTTACGCAGCAG-39) based on the sequence which
occurs between the integrase ORF and the start of the first
gene cassette (12, 16, 19, 24) was used to sequence the com-
plementary strand upstream of the integrase gene. Upstream
of the integrase ORF and its flanking structures, the nucleotide
sequence revealed the DHFR ORF of 471 bp on the comple-
mentary strand. The DHFR ORF encoded 157 amino acids
and was identified by its close nucleotide sequence homology
with dfrI (84.4%) and the close amino acid homology (90 to
63%) that it shared with the trimethoprim-resistant type I-like
DHFRs encoded by dfrI, dfrIb, dfrV, dfrV, and dfrVII (11, 24,
26, 29, 31). The ORF begin with the atypical E. coli start codon
GTG at positions 357 to 359 (Fig. 2). Despite the unusual start
codon which normally codes for valine, it is the only codon
which is preceded by a plausible Shine-Dalgarno sequence
(TAAGGAAGT). Since the ATG codon that is located five
amino acids downstream of the GTG codon is not preceded by
such a sequence, it is unlikely that this is the start codon.
Furthermore, the use of alternative E. coli start codons GTG
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and TTG in other type I-like DHFRs such as dfrI, dfrV, and
dfrVII has previously been demonstrated by experiments in-
volving N-terminal amino acid sequencing and site-directed
mutagenesis (11, 17, 26). The ORF ended with stop codon
TAA at positions 828 to 830. The translated polypeptide for
the DHFR is shown in Fig. 2. The new DHFR gene has been
named dfrXV, and the encoded polypeptide has been desig-
nated the type XV DHFR (EMBL accession no. Z83311).
dfrXV as a mobile cassette. Gene cassettes inserted into the
core site of class 1 integrons are usually flanked by a consensus
sequence (GTTRRRY) on the 59 end, which marks the point
of insertion of the gene cassette into the integron, and an im-
perfect inverted repeat known as the 59-base element, situated
39 to the resistance gene ORF (22). Similarly, dfrXV was flanked
by both a core element, which was located 16 nucleotides 59 to
the DHFR ORF and which is presumed to mark the cassette
boundary, and an inverted repeat (underlined in Fig. 2) from
nucleotides 825 to 928 at the 39 end of the DHFR ORF which
marks the 39 end of the gene cassette. The core element (GT
TAACC) differed from the consensus sequence by a single
nucleotide. Like most gene cassettes, no recognizable E. coli
promoter was present between the core element and the start
of the ORF. Sequence analysis of the upstream conserved
element (intI1) revealed a promoter region previously identi-
fied to drive the expression of inserted gene cassettes (under-
lined in Fig. 2) (12, 15, 22). This particular promoter polymor-
phism was identified as a hybrid promoter which is a promoter
with weak to moderate strength, as described previously (15).
The first promoter is followed by a second promoter which has
been identified in all class I integrons and which is thought to
be nonfunctional due to the short spacing between the 235
and 210 hexamers (15). The nucleotide sequence downstream
of the DHFR ORF was determined from pUK2412 with a
primer that was constructed from nucleotides 849 to 866, which
are located within the 59-base element. The core element at
the end of this 59-base element marks the start of the next gene
cassette (Fig. 2). From the nucleotide sequence, this cassette
was identified as the gene for streptomycin and spectinomycin
resistance aadA1 [ant(399)-Ia] (13, 32). The sequence flanking
the PstI site of pUK2412 was identical to part of the ORF of
sulI (nucleotides 986 to 1236 [24]). The junction between the
putative aadA1 and sulI genes was sequenced and was found to
be identical to the qacED1 cassette which encodes a membrane
efflux protein (21, 22) (nucleotides 211 to 480; EMBL acces-
sion no. X17479). With the exception of the DHFR gene cas-
sette, in which dfrI is substituted with dfrXV, the order of the
gene cassettes in pUK2317 is identical to that of pLMO229
(25).
Inhibition profiles of DHFR. DHFR assays were performed
by the method of Osborn and Huennekens (18) as described
previously (6). From crude cell lysates (28), the specific activity
of the DHFR, expressed in nanomoles of dihydrofolate (FH2)
reduced per minute per milligram of protein, of E. coli UI14
was 14.3, a value 14-fold higher than the specific activity of the
E. coli K-12 chromosomal enzyme. The specific activity of the
FIG. 1. Restriction map, gene map, cassette boundaries, and direction of sequencing (3) of pUK2412.
FIG. 2. Nucleotide sequence and translated polypeptide of dfrXV. The se-
quence used as a gene probe is printed in boldface type. The gene cassette
boundaries are marked (1), and the imperfect inverted repeat (59-base ele-
ment) is underlined (interrupted lines); gaps indicate mismatched bases, aster-
isks denote extra bases in the left half of the element which interrupt the inverted
repeat, and arrows (---ö) denote the direction of symmetry. The putative pro-
moter sequences of the conserved element are underlined, and the start codon of
intI1 is in italics.
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enzyme from the J62-2:pUK2317 transconjugant (10.8 nmol of
FH2 reduced/min/mg of protein) was lower, probably as a
result of host-specific differences. As a result of the high copy
number of pGEM3Zf(1) and the strong T7 promoter, the
pUK2413 clone of dfrXV produced an approximately 1,000-
fold increase in the specific activity of DHFR (1,049.1 nmol of
FH2 reduced/min/mg of protein) in comparison to that of the
E. coli JM109 host chromosomal DHFR (1.0 nmol of FH2
reduced/min/mg of protein). Partially purified DHFR was pre-
pared by ultrasonic disruption, followed by ammonium sulfate
precipitation and, finally, Sephadex G-75 gel exclusion chro-
matography as described previously (28). The approximate
inhibitor profiles and kinetic properties of the type XV DHFR
were similar to those obtained with partially purified extracts
for other DHFR enzymes of this group (Table 1). DHFR
activity was assayed in the presence of increasing concentra-
tions of trimethoprim and methotrexate to determine the
concentration required to inhibit the activity of the type XV
DHFR by 50% (ID50). In comparison to the chromosomal
DHFR of E. coli JM109 (ID50 5 0.007 mM), the type XV
DHFR (ID50 5 22.4 mM) was more than 3,000 times more
resistant to trimethoprim. The type XV DHFR was 1,500 times
more resistant to inhibition by methotrexate (ID50 5 4.4 mM)
than the chromosomal DHFR of E. coli JM109 (ID50 5 0.003
mM). The Lineweaver-Burke plots used to determine the
Michaelis constant (Km) and the inhibitor constant for tri-
methoprim (Ki) showed that the Km for the type XV DHFR
was calculated to be 16.7 mM FH2. The Ki values for tri-
methoprim at concentrations of 10 and 25 mM were 16.2 and
15.6 mM, respectively (mean Ki 5 15.9 mM FH2). Unlike the
other enzymes of this group, the type XV DHFR was found to
be extremely heat stable, even at low protein concentrations,
and could survive exposure to 45°C for more than 20 min
without any significant loss of activity.
Molecular epidemiology of dfrXV. Dot blotting was per-
formed as described previously (3). The nucleotide sequences
of dfrI and dfrXV were aligned to determine regions of max-
imum heterogeneity, and a 30-mer oligonucleotide probe
(59-ATACATTCTCATCACTGGAAGTGAAGCTTG-39)
which contained nine nucleotide mismatches compared with
the sequence of dfrI was selected for the detection of dfrXV
(boldface type in Fig. 2). This region of nucleotide sequence
heterogeneity encodes a predicted highly variable external
loop that is located between two conserved regions of the
secondary structure and that has been described previously for
the discrimination and detection of closely related DHFR
genes (1, 2, 31). Forty-six of 357 isolates of gram-negative
commensal fecal flora did not hybridize to probes for other
resistant DHFR types, and of these 26.1% (12 of 46) hybrid-
ized to the probe for dfrXV. The type XV DHFR was detected
in isolates from all three regions that were sampled in South
Africa: nine isolates were from urbanized communities in the
province of Gauteng, two isolates were from rural populations
in the Northern Province, and one isolate was from rural
Mpumalanga. Of the 12 hybridization-positive isolates, an
E. coli isolate from Gauteng did not transfer trimethoprim
resistance to an E. coli J62-2 recipient strain. Five different
EcoRI restriction profiles were obtained for the 11 plasmids
from the transconjugants which harbored dfrXV. Six isolates
harbored plasmids which shared identical restriction profiles
(pUK2317) and resistance markers (trimethoprim, sulfame-
thoxazole, tetracycline, spectinomycin), and all were isolated
from the same urban community in Gauteng. Two plasmids,
pUK2370 and pUK2369, had similar restriction profiles, and
both conferred resistance to ampicillin, trimethoprim, sulfa-
methoxazole, tetracycline, and spectinomycin. Plasmid
pUK2370 was detected in two isolates, one from Gauteng and
the other from the Northern Province, and pUK2369 was iso-
lated from Gauteng. Plasmid pUK2403, isolated from the
Northern Province, harbored another unique restriction pro-
file and conferred resistance to ampicillin, trimethoprim, sul-
famethoxazole, tetracycline, and spectinomycin. Eleven of 12
of the isolates which hybridized to the probe for dfrXV were
identified as E. coli. The remaining isolate from Mpumalanga
was a Klebsiella sp. which harbored a novel transferable plas-
mid pUK2322 which conferred resistance to trimethoprim and
sulfamethoxazole. The absence of streptomycin and spectino-
mycin resistance determinants on this plasmid suggests that
this may be a second integron context for the dfrXV cassette.
The MICs of trimethoprim conferred by these plasmids were
all greater than 2,048 mg/liter. To determine the association
and position of dfrXV among the class 1 integrons, PCR was
used to amplify the region between the intI1 and dfrXV ORFs.
PCR products of 750 bp were obtained for all 11 isolates
which harbored transferable plasmids. The size of the PCR
product suggests that the dfrXV cassette was the most recent
cassette to be inserted and was inserted immediately upstream
of the integrase gene (9, 22). No PCR product was detected in
the isolate which was unable to transfer resistance to the E. coli
recipient strain. The use of sulfonamides in combination with
trimethoprim appears to play a significant role in the selection
of sulI-associated integrons and has presumably applied
strong selection pressure for the uptake of new trimethoprim
resistance cassettes by these elements.
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